Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RUSSELL MACBAIN PECKHAM

Allopathic & Osteopathic Physicians Dermatology

NPI
1801816715
CMS profile
841465
Location
ROUND ROCK, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$3,542.46

175 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,443.46 174
Education $99.00 1

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 175 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RUSSELL MACBAIN PECKHAM

NPI 1801816715 · CMS profile ID 841465

Allopathic & Osteopathic Physicians / Dermatology

ROUND ROCK, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 175 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1801816715?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RUSSELL MACBAIN PECKHAM, NPI 1801816715, CMS profile ID 841465. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 175 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1801816715?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). RUSSELL MACBAIN PECKHAM, NPI 1801816715, CMS profile ID 841465. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 175 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1801816715?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
RUSSELL MACBAIN PECKHAM, NPI 1801816715, CMS profile ID 841465, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 175 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1801816715?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

175 matching records · $3,542.46 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 175 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 175.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $16.4706/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999360955 CMS
Novartis Pharmaceuticals Corporation $19.8106/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992918863 CMS
PFIZER INC. $7.9205/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050675001 CMS
ABBVIE INC. $21.9705/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998115055 CMS
Dermavant Sciences, Inc. $14.2205/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991236467 CMS
GENZYME CORPORATION $14.8305/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049942325 CMS
E.R. Squibb & Sons, L.L.C. $10.2405/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015476589 CMS
Arcutis Biotherapeutics, Inc. $17.1605/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044846243 CMS
Janssen Biotech, Inc. $27.2905/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988752301 CMS
ABBVIE INC. $20.8705/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998115051 CMS
E.R. Squibb & Sons, L.L.C. $12.3605/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015476585 CMS
PFIZER INC. $27.9505/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050383681 CMS
ABBVIE INC. $16.8705/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998115047 CMS
Janssen Biotech, Inc. $18.8805/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988752303 CMS
PFIZER INC. $21.0305/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049201855 CMS
GENZYME CORPORATION $30.8204/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049942321 CMS
Incyte Corporation $20.9104/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044163763 CMS
Janssen Biotech, Inc. $15.8504/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988752295 CMS
UCB, Inc. $134.9304/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021599867 CMS
Galderma Laboratories, L.P. $14.9604/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059718647 CMS
Regeneron Healthcare Solutions, Inc. $7.0104/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999360949 CMS
ABBVIE INC. $26.1504/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998115043 CMS
Novartis Pharmaceuticals Corporation $25.7104/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992918855 CMS
Dermavant Sciences, Inc. $12.1804/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991236463 CMS
ABBVIE INC. $18.3604/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998115039 CMS
ABBVIE INC. $25.7904/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998115035 CMS
Arcutis Biotherapeutics, Inc. $1.7904/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044846255 CMS
Sun Pharmaceutical Industries Inc. $26.4804/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053962367 CMS
E.R. Squibb & Sons, L.L.C. $16.1004/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015476557 CMS
PFIZER INC. $7.2004/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049128465 CMS
Dermavant Sciences, Inc. $14.9803/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991236459 CMS
E.R. Squibb & Sons, L.L.C. $7.8703/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015476553 CMS
PFIZER INC. $21.5703/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050689835 CMS
GENZYME CORPORATION $29.4303/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049942283 CMS
Janssen Biotech, Inc. $30.2503/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988752289 CMS
ABBVIE INC. $28.5103/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998115031 CMS
Regeneron Healthcare Solutions, Inc. $21.4403/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999360943 CMS
ABBVIE INC. $18.8303/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998115027 CMS
Dermavant Sciences, Inc. $14.1103/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991236455 CMS
Janssen Biotech, Inc. $10.8903/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988752287 CMS
E.R. Squibb & Sons, L.L.C. $9.2103/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015476597 CMS
ABBVIE INC. $27.8303/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998115023 CMS
ABBVIE INC. $21.5603/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998115019 CMS
PFIZER INC. $18.6903/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050401303 CMS
Arcutis Biotherapeutics, Inc. $8.0203/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044846271 CMS
E.R. Squibb & Sons, L.L.C. $9.7402/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015476541 CMS
Novartis Pharmaceuticals Corporation $20.0702/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992918859 CMS
Dermavant Sciences, Inc. $18.3202/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991236451 CMS
PFIZER INC. $4.2402/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049373659 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $34.3102/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997154447 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,259.25 64
PY2020 $1,002.80 47
PY2021 $2,076.90 115
PY2022 $3,650.52 196
PY2023 $3,542.46 175
PY2024 $3,419.64 165
PY2025 $3,314.31 159

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $165,885.23 33
PY2024 Principal investigator $3,058.80 1
PY2023 Principal investigator $11,000.00 1
PY2022 Principal investigator $5,000.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

33 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,529.40 12/31/2025 Non-covered Recipient Entity
OLIVER STREET DERMA HOLDINGS LLC
A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata No dispute reported 06/30/2026 1202533773
Principal investigator 1 ABBVIE INC. $3,330.00 12/30/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202532238
Principal investigator 1 ABBVIE INC. $8,304.75 12/04/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202528816
Principal investigator 1 ABBVIE INC. $2,216.10 12/04/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202528818
Principal investigator 1 ABBVIE INC. $1,847.55 11/05/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202522633
Principal investigator 1 ABBVIE INC. $1,695.00 11/04/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202520871
Principal investigator 1 ABBVIE INC. $7,536.00 10/09/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202516411
Principal investigator 1 ABBVIE INC. $2,078.40 10/09/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202516423
Principal investigator 1 ABBVIE INC. $1,920.45 09/04/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202508508
Principal investigator 1 ABBVIE INC. $2,216.10 09/03/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202507173
Principal investigator 1 ABBVIE INC. $1,847.55 08/06/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202502931
Principal investigator 1 ABBVIE INC. $7,536.00 07/08/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202497358
Principal investigator 1 ABBVIE INC. $2,033.85 07/02/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202495993
Principal investigator 1 ABBVIE INC. $1,920.45 06/03/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202487411
Principal investigator 1 ABBVIE INC. $4,470.00 06/03/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202487413
Principal investigator 1 ABBVIE INC. $3,695.10 05/07/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202484071
Principal investigator 1 ABBVIE INC. $821.48 04/03/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202469421
Principal investigator 1 ABBVIE INC. $3,828.75 04/03/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202469446
Principal investigator 1 ABBVIE INC. $6,694.95 03/07/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202460321
Principal investigator 1 ABBVIE INC. $3,828.75 03/07/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202461104
Principal investigator 1 ABBVIE INC. $1,981.20 02/06/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202448955
Principal investigator 1 ABBVIE INC. $5,243.55 02/06/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202449023
Principal investigator 1 ABBVIE INC. $6,219.45 01/24/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202441164
Principal investigator 1 ABBVIE INC. $7,037.00 01/24/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202441168
Principal investigator 1 ABBVIE INC. $8,563.95 01/24/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202441171
Principal investigator 1 ABBVIE INC. $3,962.40 01/24/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202441175
Principal investigator 1 ABBVIE INC. $1,957.65 01/24/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202441177
Principal investigator 1 ABBVIE INC. $2,073.75 01/24/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202441181
Principal investigator 1 ABBVIE INC. $16,574.25 01/24/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202441186
Principal investigator 1 ABBVIE INC. $1,998.75 01/24/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202441190
Principal investigator 1 ABBVIE INC. $13,000.00 01/24/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202441194
Principal investigator 1 ABBVIE INC. $15,973.50 01/24/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202441198
Principal investigator 1 ABBVIE INC. $11,949.15 01/24/2025 Non-covered Recipient Entity
OLIVER STREET 501 (A) INC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202441202